Thomas-Toan Tran
Intarcia Therapeutics (United States)(US)
Publications by Year
Research Areas
Neutrophil, Myeloperoxidase and Oxidative Mechanisms, Chronic Myeloid Leukemia Treatments, Macrophage Migration Inhibitory Factor, Monoclonal and Polyclonal Antibodies Research, HER2/EGFR in Cancer Research
Most-Cited Works
- → Location Matters: Site of Conjugation Modulates Stability and Pharmacokinetics of Antibody Drug Conjugates(2013)488 cited
- → Molecular Basis of Valine-Citrulline-PABC Linker Instability in Site-Specific ADCs and Its Mitigation by Linker Design(2016)201 cited
- → Sonic Hedgehog regulates Hes1 through a novel mechanism that is independent of canonical Notch pathway signalling(2007)170 cited
- → Site-specific conjugation improves therapeutic index of antibody drug conjugates with high drug loading(2015)166 cited
- → Effect of Attachment Site on Stability of Cleavable Antibody Drug Conjugates(2015)148 cited
- → RN927C, a Site-Specific Trop-2 Antibody–Drug Conjugate (ADC) with Enhanced Stability, Is Highly Efficacious in Preclinical Solid Tumor Models(2016)99 cited
- → Inhibiting TGF-β signaling restores immune surveillance in the SMA-560 glioma model(2007)94 cited
- → Transforming Growth Factor-β Receptor Type 1 (TGFβRI) Kinase Activity but Not p38 Activation Is Required for TGFβRI-Induced Myofibroblast Differentiation and Profibrotic Gene Expression(2006)75 cited
- → Site-Dependent Degradation of a Non-Cleavable Auristatin-Based Linker-Payload in Rodent Plasma and Its Effect on ADC Efficacy(2015)63 cited
- → A novel CXCR4 antagonist IgG1 antibody (PF-06747143) for the treatment of hematologic malignancies(2017)50 cited